Cell Source, Inc. (CLCS)
| Market Cap | 55.72M +197.2% |
| Revenue (ttm) | n/a |
| Net Income | -5.89M |
| EPS | -0.14 |
| Shares Out | 67.95M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,100 |
| Average Volume | 2,806 |
| Open | 0.8200 |
| Previous Close | 0.8200 |
| Day's Range | 0.8200 - 0.8200 |
| 52-Week Range | 0.1819 - 2.2500 |
| Beta | -195.86 |
| RSI | 49.94 |
| Earnings Date | May 21, 2026 |
About Cell Source
Cell Source, Inc., a biotechnology company, engages in developing cell therapy treatments based on the management of immune tolerance. Its lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. The company’s Veto Cell technology is used in various applications, including treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell transplantation acceptance, as well as treatment of end stage kidney disea... [Read more]
Financial Performance
Financial StatementsNews
Cell Source Announces Closing of Private Placement and Hiring of Transfer Agent
NEW YORK CITY, NEW YORK / ACCESS Newswire / January 15, 2026 / Cell Source, Inc. (OTC Pink Limited:CLCS) ("Cell Source" or the "Company"), a leading innovator in immune tolerance management, announced...
Cell Source Presents Potential Breakthrough in the Development of Off-the-Shelf CAR-T Cell Therapy at American Society of Hematology Annual Meeting
Research Presented at the American Society of Hematology Annual Meeting Highlights New Mechanisms to Overcome Immune Rejection NEW YORK, NY / ACCESSWIRE / December 19, 2024 / Cell Source, Inc. (OTCQB:...
Cell Source announces interim results from Veto Cell clinical trial
Cell Source (CLCS) shared interim results from its Phase 1/2 First-in-Human clinical trial conducted at The University of Texas MD Anderson Cancer Center. The trial has treated 15 patients using…